PURPOSE: To evaluate incidence and predictive factors for the vascular lake phenomenon (VLP), as well as to compare local and overall tumor response in patients with and without VLP induced during DEB-TACE for HCC. METHODS: A total of 200 consecutive patients with 323 HCC nodules underwent first-session DEB-TACE from 2011 to 2014. Patients were divided in two groups, according to the presence of the VLP during DEB-TACE. Pre- and post-treatment imaging studies (CT or MRI) were performed. Primary endpoint was assessment of tumor response, evaluated by mRECIST. Comparison of response rates between the VLP group and the non-VLP group was performed. Secondary endpoints were the determination of incidence rate and predictive factors for the VLP. RESULTS: The VLP was observed in 39/323 (12.1%) of the nodules treated. At multivariate logistic regression analysis, tumor size ≥3 cm in diameter (OR 13.95; 95% CI 3.60-54.05), presence of a pseudocapsule (OR 6.67; 95% CI 1.45-30.59) and alpha-fetoprotein levels (OR 1.004; 95% CI 1.000-1.007) remained predictive for the VLP occurrence. On a nodule-based analysis (p < 0.001), target lesion response analysis (p = 0.003) and overall response analysis (p = 0.004) the VLP group presented a higher objective response rate than the non-VLP group. CONCLUSION: VLP is observed in 12% of the patients and happens more frequently in large and encapsulated tumors. It seems to be associated with better local and overall responses in HCC patients who underwent DEB-TACE.
PURPOSE: To evaluate incidence and predictive factors for the vascular lake phenomenon (VLP), as well as to compare local and overall tumor response in patients with and without VLP induced during DEB-TACE for HCC. METHODS: A total of 200 consecutive patients with 323 HCC nodules underwent first-session DEB-TACE from 2011 to 2014. Patients were divided in two groups, according to the presence of the VLP during DEB-TACE. Pre- and post-treatment imaging studies (CT or MRI) were performed. Primary endpoint was assessment of tumor response, evaluated by mRECIST. Comparison of response rates between the VLP group and the non-VLP group was performed. Secondary endpoints were the determination of incidence rate and predictive factors for the VLP. RESULTS: The VLP was observed in 39/323 (12.1%) of the nodules treated. At multivariate logistic regression analysis, tumor size ≥3 cm in diameter (OR 13.95; 95% CI 3.60-54.05), presence of a pseudocapsule (OR 6.67; 95% CI 1.45-30.59) and alpha-fetoprotein levels (OR 1.004; 95% CI 1.000-1.007) remained predictive for the VLP occurrence. On a nodule-based analysis (p < 0.001), target lesion response analysis (p = 0.003) and overall response analysis (p = 0.004) the VLP group presented a higher objective response rate than the non-VLP group. CONCLUSION: VLP is observed in 12% of the patients and happens more frequently in large and encapsulated tumors. It seems to be associated with better local and overall responses in HCCpatients who underwent DEB-TACE.
Authors: Fuad Nurili; Sebastien Monette; Adam O Michel; Achiude Bendet; Olca Basturk; Gokce Askan; Christopher Cheleuitte-Nieves; Hooman Yarmohammadi; Aaron W P Maxwell; Etay Ziv; Kyle M Schachtschneider; Ron C Gaba; Lawrence B Schook; Stephen B Solomon; F Edward Boas Journal: J Vasc Interv Radiol Date: 2021-01-23 Impact factor: 3.464
Authors: Breno Boueri Affonso; Francisco Leonardo Galastri; Joaquim Mauricio da Motta Leal Filho; Felipe Nasser; Priscila Mina Falsarella; Rafael Noronha Cavalcante; Marcio Dias de Almeida; Guilherme Eduardo Gonçalves Felga; Leonardo Guedes Moreira Valle; Nelson Wolosker Journal: World J Gastroenterol Date: 2019-10-07 Impact factor: 5.742
Authors: Tajana Filipec Kanižaj; Petra Dinjar Kujundžić; Ana Ostojić; Maja Mijić; Helga Sertić Milić; Ana Mijić; Matija Mateljak; Dora Martinčević; Eva Radetić; Vinko Vidjak; Branislav Kocman; Ivana Mikolašević Journal: Croat Med J Date: 2022-08-31 Impact factor: 2.415